Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
97.72%
Operating Margin
67.51%
Net Margin
53.03%
Efficiency Metrics
Revenue per Expense Ratio
3.08
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
97.90%
Income Tax Rate
0.33%
EPS
1.2500000000
Balance Sheet Analysis
Current Ratio
4.73
Cash Ratio
0.51
Working Capital
$292.78M
Debt to Equity
0.57
Debt to Assets
35.46%
Equity Ratio
62.47%
Cash Flow Analysis
Operating Cash Flow Ratio
70.79%
Free Cash Flow Ratio
-177.97%
CapEx to Revenue
248.77%
Dividends Paid
$168.23M
Stock Buybacks
$3.67M
Total Shareholder Returns
$171.90M
Cash Position Change
-31.52%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 5.31%
Detailed Growth Metrics
Core Performance
Revenue
25.51%
Net Income
42.18%
EPS
26.26%
Operating Income
38.38%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
4.12%
Operating Cash Flow
20.64%
Free Cash Flow
149.17%
Balance Sheet Health
Assets
19.21%
Debt
19.02%
Book Value per Share
6.11%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
5.31%
Shares Outstanding
12.75%
Long Term Trends
3Y Revenue/Share
37.35%
5Y Revenue/Share
4.73%
3Y Dividend/Share
21.87%
5Y Dividend/Share
235.11%